ebola
outbreak
west
africa
trigger
global
crisi
nine
countri
report
infect
case
total
nearli
live
lost
actual
death
toll
like
much
higher
figur
death
rate
high
consid
confirm
case
ebola
viru
launch
destruct
shut
host
innat
adapt
immun
system
viru
replic
control
caus
cytokin
storm
host
consequ
host
overdriven
immun
system
attack
endotheli
cell
lead
multipl
organ
hemorrhag
damag
host
die
septic
shock
final
current
circumst
specif
intervent
shown
effect
viru
opinion
justifi
appli
nonspecif
antivir
approach
incub
period
viru
infect
essenti
protect
put
host
immun
system
alert
state
henceforth
slow
viral
replic
viral
infect
proce
termin
stage
key
factor
would
appli
nonspecif
immun
modul
approach
suppress
cytokin
storm
caus
multipl
organ
failur
attempt
open
time
window
host
immun
system
recov
ebola
viru
invad
antigen
present
cell
apc
quietli
turn
alarm
system
essenti
immun
system
remain
inactiv
toward
viru
viru
grow
uncontrol
invad
mani
organ
eventu
mani
prematur
cell
start
die
explod
cell
releas
content
includ
signal
molecul
blood
signal
eventu
trigger
extrem
immun
attack
caus
arteri
vein
capillari
leak
blood
plasma
host
bodi
temperatur
drop
blood
pressur
fall
caus
host
go
sever
septic
shock
shown
ebola
viru
primarili
target
macrophag
dendrit
cell
dc
later
membraneassoci
glycoprotein
gp
viru
bind
endotheli
cell
caus
cell
death
vascular
permeabl
latter
allow
viru
spread
vital
organ
execut
sever
extens
damag
bodi
symptom
bleed
appear
viru
gain
entri
hepatocyt
caus
liver
failur
although
neutrophil
lymphocyt
natur
killer
nk
cell
appear
remain
uninfect
cell
undergo
bystand
apoptosi
presum
induc
inflammatori
mediat
andor
loss
support
signal
dc
dissemin
region
lymph
node
result
round
viru
replic
follow
spread
bloodstream
dc
fix
mobil
macrophag
liver
spleen
thymu
lymphoid
tissu
result
extens
tissu
necrosi
mohamadzadeh
et
al
ansari
fig
ebola
viru
appli
multipl
physic
biolog
mechan
evad
host
innat
acquir
humor
cellular
immun
respons
interferon
ifn
belong
cytokin
use
commun
cell
trigger
protect
defens
immun
system
help
erad
pathogen
inhibit
ifn
alarm
seem
one
import
aspect
pathogenesi
ebola
viru
primarili
antagon
respons
target
cell
especi
macrophag
monocyt
dc
util
viral
protein
block
phosphoryl
ifn
regulatori
factor
act
transcript
factor
ifn
product
et
al
wherea
block
ifnmedi
antivir
respons
xu
et
al
macrophag
play
critic
role
nonspecif
defens
also
help
initi
specif
defens
mechan
recruit
immun
cell
lymphocyt
massiv
infect
macrophag
relat
cell
ebola
viru
indic
abl
block
evad
cell
innat
antivir
mechan
nk
cell
respond
antigenindepend
manner
viral
infect
kill
infect
cell
nk
cell
number
dramat
drop
cours
infect
almost
undergo
apoptosi
dc
crucial
role
innat
adapt
immun
howev
infect
dc
produc
proinflammatori
cytokin
costimulatori
molecul
abil
support
tcell
prolifer
thu
impair
infect
dc
undergo
anomal
matur
hoenen
et
al
impair
apc
function
lymphocyt
apoptosi
contribut
failur
specif
immun
respons
ebola
trigger
system
dysregul
immun
like
result
uncontrol
viru
replic
macrophageproduc
proinflammatori
cytokin
key
player
host
defens
system
pathogen
patient
ebola
viral
burden
elev
time
trigger
extrem
strong
immun
attacka
phenomenon
call
cytokin
storm
sullivan
et
al
monocyt
andor
macrophag
produc
massiv
amount
proinflammatori
cytokin
includ
tumor
necrosi
interleukin
il
figur
creat
refer
mohamadzadeh
et
al
combin
consider
nk
natur
killer
tnf
tumor
necrosi
factor
il
interleukin
mcsf
macrophag
colonystimul
factor
mip
macrophag
inflammatori
protein
mcp
macrophagemonocyt
chemotact
protein
nitric
oxid
sgp
solubl
viru
glycoprotein
chemokin
macrophag
inflammatori
protein
macrophagemonocyt
chemotact
macrophag
colonystimul
factor
mcsf
nitric
oxid
eotaxin
baiz
et
al
bodi
respons
ebola
infect
would
sever
late
cytokin
storm
lead
exagger
inflammatori
respons
contribut
lymphoid
cell
apoptosi
sepsi
ansari
viru
eventu
disabl
vascular
system
caus
blood
leakag
combin
massiv
viremia
intravascular
coagulopathi
termin
stage
viru
infect
usual
includ
diffus
bleed
hypotens
shock
would
eventu
kill
patient
ebola
infect
gener
compos
incub
period
symptomaticacut
stage
convalescenttermin
stage
viru
burden
inflammatori
respons
specif
antibodi
main
contributor
differ
outcom
mortal
surviv
symptomless
infect
fig
suggest
appropri
intervent
strategi
stage
would
accordingli
abl
control
ebola
viru
whether
inflammatori
respons
execut
protect
damag
effect
depend
specif
cytokin
profil
also
delic
balanc
individu
host
immun
respons
incom
viru
sullivan
et
al
patient
delay
prolong
inflammatori
respons
lead
cytokin
storm
character
extrem
high
circul
level
numer
proinflammatori
cytokin
patient
gener
surviv
viral
infect
misasi
sullivan
averag
level
proinflammatori
cytokin
patient
blood
found
time
higher
patient
recov
viral
infect
wauquier
et
al
ansari
survivor
tend
shortliv
balanc
proand
antiinflammatori
respons
character
presenc
earli
clinic
cours
bray
mahanti
detect
either
survivor
nonsurvivor
wauquier
et
al
viral
infect
case
asymptomat
immedi
proper
inflammatori
respons
critic
case
character
transient
high
level
plasma
within
first
put
infecti
contact
baxter
leroy
et
al
baiz
et
al
believ
case
viral
replic
suppress
effect
inflammatori
respons
infect
patient
develop
proper
inflammatori
respons
wherea
other
remain
unclear
nonetheless
phenomenon
give
clue
treatment
ebola
viru
diseas
evd
earli
activ
innat
immun
respons
may
prevent
viral
infect
prompt
appropri
adapt
immun
respons
ebola
seem
import
resolut
infect
virusspecif
humor
cellular
mechan
requir
clear
viral
infect
humor
immun
import
acut
stage
halt
viral
spread
wherea
cellular
immun
import
elimin
virusinfect
cell
could
continu
serv
sourc
viru
ansari
fatal
case
found
associ
defect
humor
respons
without
specif
igg
product
case
low
level
specif
igm
detect
patient
baiz
et
al
ksiazek
et
al
survivor
gener
associ
significantli
earli
emerg
specif
humor
respons
regul
activ
cytotox
cell
coincid
clearanc
viral
antigen
blood
survivor
produc
specif
igm
earli
first
symptom
onset
specif
igg
baiz
et
al
ksiazek
et
al
asymptomat
individu
produc
specif
igm
igg
within
week
initi
exposur
viral
sourc
antibodi
product
reach
moder
level
one
month
later
leroy
et
al
outcom
earli
viral
load
unclear
viral
titer
plasma
undetect
incub
period
wherea
viru
load
similar
fatal
survivor
first
day
symptom
stage
typic
million
copi
ebola
viru
per
millilit
plasma
reach
earli
two
day
onset
symptom
fatal
case
level
circul
antigen
keep
rise
death
moreov
viru
load
near
time
death
greater
fatal
case
comparison
nonfat
case
schieffelin
et
al
survivor
plasma
often
contain
fewer
copi
viru
per
millilit
plasma
level
circul
antigen
began
declin
onset
symptom
drop
undetect
level
patient
recov
baiz
et
al
hoenen
et
al
viral
load
lowest
asymptomat
individu
viru
rna
detect
subject
three
week
initi
exposur
leroy
et
al
baiz
et
al
ebola
viru
undergo
massiv
bystand
apoptosi
hoenen
et
al
strong
deplet
lymphocyt
plasma
cell
found
fatal
case
geisbert
et
al
follow
extens
intravascular
apoptosi
vascular
dysfunct
loss
endotheli
barrier
function
kill
patient
baiz
et
al
symptomat
stage
support
care
mainli
toward
aggress
prevent
intravascular
volum
deplet
correct
profound
electrolyt
abnorm
prevent
shock
complic
fowler
et
al
neither
precaut
incub
period
effect
medic
termin
stage
propos
prevent
antivir
intervent
incub
period
may
lower
consequ
viru
burden
furthermor
propos
immunomodulatori
strategi
termin
stage
may
reduc
damag
caus
cytokin
storm
thu
prolong
surviv
time
patient
make
possibl
patient
adopt
immun
recov
beat
infect
type
ifn
cytokin
secret
infect
cell
induc
cellintrins
antivir
state
infect
neighbor
cell
also
modul
innat
immun
respons
balanc
manner
activ
adapt
immun
system
le
bon
tough
ivashkiv
donlin
fig
figur
creat
refer
ivashkiv
donlin
combin
consider
ifn
interferon
dc
dendrit
cell
isg
interferonstimul
gene
type
ifn
broad
spectrum
antivir
capabl
abl
fight
viru
infect
give
exampl
recombin
shown
signific
nonspecif
inhibit
herp
simplex
viru
influenza
viru
sever
acut
respiratori
syndrom
sar
coronari
viru
replic
cao
et
al
ebola
viru
block
product
type
ifn
apc
includ
dc
macrophag
also
block
ifnmedi
antivir
respons
viru
protein
crucial
mechan
wherebi
virus
evad
attack
host
immun
system
directli
howev
recombin
iuml
suppress
ebola
replic
vero
cell
vitro
earli
treatment
ebolainfect
cynomolgu
recombin
delay
onset
viremia
death
sever
day
jahrl
et
al
addit
treatment
associ
reduc
plasma
tissu
viral
burden
thu
significantli
increas
surviv
time
macaqu
infect
ebola
viru
vivo
smith
et
al
collect
result
indic
type
ifn
may
therapeut
potenti
reason
postul
direct
effect
viral
replic
well
adapt
immun
respons
observ
viru
titer
detect
incub
period
indic
vast
major
cell
infect
ebola
viru
base
fact
suggest
exogen
administr
type
ifn
may
induc
uninfect
cell
antivir
state
type
ifn
might
limit
spread
ebola
viru
prolong
surviv
administ
immedi
exposur
ebola
virus
patient
inde
recov
ebola
infect
without
receiv
specif
intervent
despit
ebola
infect
high
mortal
rate
fact
suggest
appropri
immun
respons
help
bodi
heal
outcom
highli
depend
two
cellularlevel
compet
mechan
apoptosi
endotheli
cell
execut
autoimmun
attack
vascular
regener
stem
cell
interestingli
patient
age
year
lower
fatal
rate
wherea
fatal
rate
age
year
two
age
group
fatal
rate
schieffelin
et
al
stem
cell
essenti
regen
process
almost
tissu
organ
signific
differ
indic
patient
cellularlevel
heal
capac
differ
age
group
may
relev
consumpt
agerel
chang
stem
cell
reservoir
suggest
treatment
mesenchym
stromal
cell
msc
termin
stage
evd
consid
msc
mesodermorigin
multipot
cell
exist
mani
tissu
capabl
differenti
sever
differ
cell
type
number
potenti
msc
popul
adult
organ
declin
age
stolz
et
al
toledano
et
al
exogen
administr
msc
migrat
injur
tissu
site
inhibit
releas
proinflammatori
cytokin
promot
surviv
damag
cell
msc
oper
varieti
effector
mechan
key
cell
innat
adapt
immun
system
mostli
manipul
cell
cycl
induc
matur
arrest
without
apoptosi
tyndal
pistoia
therapeut
effect
msc
may
depend
larg
capac
msc
regul
inflamm
tissu
homeostasi
via
array
immunosuppress
factor
cytokin
growth
factor
differenti
factor
msc
reduc
inflamm
shut
pathway
immun
cell
activ
prevent
cytokin
storm
inhibit
disabl
tcell
respons
msc
reprogram
macrophag
neutrophil
nk
cell
dc
lymphocyt
b
lymphocyt
counteract
sepsi
plock
et
al
fig
msc
specif
commun
inflammatori
microenviron
immunoregulatori
function
msc
highli
plastic
stimul
tissu
repair
mitogen
angiogen
effect
msc
inhibit
ongo
inflamm
apoptosi
later
fibrosi
injur
tissu
support
endotheli
cell
growth
blood
vessel
repair
strategi
help
avoid
abus
steroid
hormon
variou
sequela
report
graftversushost
diseas
gvhd
system
lupu
erythematosu
sle
sepsi
success
treat
msc
kebriaei
et
al
sun
et
al
wannemuehl
et
al
pedrazza
et
al
would
interest
use
avail
nonhuman
primat
model
evd
test
therapeut
hypothesi
almost
year
sinc
first
ebola
outbreak
date
effect
therapeut
prophylact
intervent
avail
prevent
infect
sever
experiment
intervent
earli
stage
develop
avail
limit
intermitt
zhang
wang
posit
result
observ
sever
case
zmapp
tkmebola
administr
unclear
whether
posit
outcom
due
drug
due
better
support
care
western
countri
africa
clinic
trial
ebola
vaccin
develop
merck
newlink
suspend
due
unexpect
side
effect
recent
meanwhil
san
msf
select
three
exist
intervent
clinic
trial
favipiravir
approv
japan
treat
influenza
brincidofivir
approv
usa
viru
treatment
ebola
convalesc
serum
might
present
less
suppli
challeng
alreadi
approv
purpos
howev
preliminari
data
show
potenc
ebola
viru
limit
outlook
develop
ebola
therapeut
optimist
mani
differ
kind
virus
virus
mutat
dnarna
signatur
evolv
rapidli
specif
therapi
even
common
human
viral
infect
hbv
hcv
hiv
hpv
avian
influenza
realist
nonspecif
treatment
essenti
strategi
viral
diseas
forese
futur
immun
system
given
suffici
time
intent
activ
expos
deadli
plock
et
al
combin
consider
nk
natur
killer
il
interleukin
prostaglandin
ido
indoleamin
solubl
human
leukocyt
tnfr
tumor
necrosi
factor
receptor
ifn
interferon
egf
epiderm
growth
factor
virus
good
chanc
gear
elimin
virus
